Study of VX-407 and oral contraceptive interaction
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how a new drug, VX-407, affects the levels of a combined oral contraceptive in your body. Participants must be healthy adults aged 18 to 65 with a certain body weight and BMI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are you between 18 and 65 years old?
- Is your Body Mass Index (BMI) between 18.0 and 30.0 kg/m2?
- Do you weigh more than 50 kilograms (about 110 pounds)?
- Have you had a fever or illness with fever in the last 5 days?
- Are you currently pregnant, planning to become pregnant, or breastfeeding?
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives a single dose of the study drug VX-407 to see how it is absorbed, broken down, and removed from the body. It helps researchers understand how the drug works in people.
This trial checks how a new drug interacts with two other medicines (amiodarone and febuxostat) in healthy volunteers. It helps doctors understand safe dosing before testing in patients.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
This study tests whether following a special diet for one week can help people with polycystic kidney disease. It aims to see if the diet is safe and if it can slow down the disease.
This study tests whether a specific diet can lower a marker of inflammation in the urine, which may help slow kidney damage in people with autosomal dominant polycystic kidney disease (ADPKD).
This study is for healthy volunteers to see how a new experimental drug (JMKX003142) interacts with other drugs in the body. It helps find the right dose for future patients.
Hear when a new Autosomal Dominant Polycystic Kidney Disease (ADPKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.